Get the Stockscreener App
625.65
2.37%
-15.21
After Hours:
625.80
0.15
+0.02%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $625.65, with a volume of 14.08M.
It is down -2.37% in the last 24 hours and down -19.55% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$640.86
Open:
$655
24h Volume:
14.08M
Relative Volume:
3.37
Market Cap:
$592.95B
Revenue:
$53.26B
Net Income/Loss:
$13.80B
P/E Ratio:
40.89
EPS:
15.3
Net Cash Flow:
$-50.20M
1W Performance:
-17.93%
1M Performance:
-19.55%
6M Performance:
-28.77%
1Y Performance:
-25.99%
1-Day Range:
$623.78
$656.18
1-Week Range:
$623.78
$774.48
52-Week Range:
$623.78
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
625.65 | 670.04B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
173.33 | 410.84B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
198.05 | 346.78B | 58.33B | 3.76B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
116.84 | 219.72B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
80.69 | 198.42B | 63.62B | 16.41B | 14.72B | 6.49 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Lilly launches "The Court Is Hers™" to help more girls get in the game - Eli Lilly and Company
Eli Lilly (LLY) Partners With Senderra For Innovative Digital Patient Care Solution - uk.finance.yahoo.com
Eli Lilly’s Stock Dips Amid Weight-Loss Pill Setback - TipRanks
Earnings Beat: Eli Lilly and Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - 富途牛牛
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $825 to $1,190 - 富途牛牛
Benzinga Bulls And Bears: AMD, Apple, Eli Lilly — And Wall Street Treads Water - Benzinga
IonQ, Eli Lilly, Monster, Crocs, Kratos Trending by Analysts - TipRanks
BMO Raises Eli Lilly (LLY) Price Target, Keeps Outperform Rating - Insider Monkey
Director’s Bold Move: Major Investment in Eli Lilly & Co Stock - TipRanks
Why Novo Nordisk Stock Flew Higher on Friday - The Motley Fool
Lilly Shares Slide Following Weight Loss Pill Trial Results - InkFreeNews.com
Celltrion in talks to buy Eli Lilly plant in US for $504 million - KED Global
Eli Lilly's Orforglipron Data Is Not Disastrous: Analyst - Benzinga
Is Eli Lilly's 14% Post-Earnings Slide a Buy-the-Dip Opportunity? - MSN
ETFs In Focus On Eli Lilly's Solid Q2 Earnings, Weak Obesity Data - Barchart.com
Eli Lilly Stock Collapsed On Its Shocking Obesity Flop — Is It Now A Sell? - Investor's Business Daily
Eli Lilly stock rating reiterated at Overweight by JPMorgan - Investing.com South Africa
Eli Lilly Stock (LLY) Continues to Sink as Enthusiasm for Obesity Pill Fades - TipRanks
Eli Lilly: 50% Upside For LLY Stock? - Forbes
Eli Lilly stock price target lowered to $895 by UBS on orfo data concerns - Investing.com
Eli Lilly defends itself after disappointing obesity data: “It’s tough to compare" - medwatch.com
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried? - The Motley Fool
Eli Lilly and Company (NYSE:LLY) Q2 2025 Earnings Call Transcript - Insider Monkey
Novo Nordisk execs respond to rival's tablet data: "We can make a really great launch in the US” - medwatch.com
Eli Lilly’s once daily oral pill shows major weight loss in trials: Is this easier to use than taking a shot? - The Indian Express
Morgan Stanley reiterates Overweight rating on Eli Lilly stock, citing GLP-1 growth - Investing.com
Eli Lilly price target lowered to $895 from $1,050 at UBS - TipRanks
Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY) - StreetInsider
Morgan Stanley trims Eli Lilly price target, calls selloff ‘overdone’ - TipRanks
Eli Lilly & Co: Strong Buy Rating Backed by Robust Performance and Growth Prospects - TipRanks
Eli Lilly Earnings: Weak Orforglipron Obesity Data Weighs Down a Strong Quarter - Morningstar
Eli Lilly sees challenges in the US: Compounders are rampant while CVS prefers Novo Nordisk - medwatch.com
Eli Lilly and Company (NYSE: LLY) | Stock Quote, Chart, Outlook - AskTraders.com
Eli Lilly and Co (LLY) Q2 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Eli Lilly and Co (LLY) Q2 2025 Earnings Call Highlights: Record - GuruFocus
Eli Lilly, a U.S. pharmaceutical company that has led the world's largest anti-obesity drug market - 매일경제
Eli Lilly's orforglipron achieves weight loss goal but stock drops 14%CHOSUNBIZ - Chosunbiz
Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound - Stocktwits
Eli Lilly (LLY) Stock: Drops 14% Despite 38% Revenue Growth Led by Zepbound and Mounjaro - CoinCentral
Chugai Highlights Eli Lilly’s Positive Phase 3 Results for Orforglipron - TipRanks
Eli Lilly's Share Price Sheds Some Weight: This Doesn't Mean To Pile In (NYSE:LLY) - Seeking Alpha
Eli Lilly could get $100M in tax credits for Wisconsin expansion - Finance & Commerce
Pill-version of popular weight loss drugs could be available, Eli Lilly officials say - WUSA9
Lilly's beat-and-raise quarter can't escape orforglipron's shadow - FirstWord Pharma
Earnings live: Eli Lilly stock slides, Pinterest sells off, Block gains after hours - ca.finance.yahoo.com
Earnings live: Eli Lilly stock slides, Pinterest sells off, Expedia and Block gain after hours - uk.finance.yahoo.com
Lilly Falls as Weight-Loss Pill Data Overshadows Sales Beat - Bloomberg.com
Closing a zombie biotech, and Lilly’s disappointing obesity readout - statnews.com
Eli Lilly stock sell-off ‘overdone’ as weight-loss pill remains ‘commercially viable’ - Invezz
Eli Lilly weight loss pill shows promise, but not as strong as injectables - AOL.com
Why Eli Lilly (LLY) Shares Are Getting Obliterated Today - Yahoo Finance
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):